Core Insights - Lexicon Pharmaceuticals is presenting clinical data for pilavapadin, an investigational AAK1-inhibitor aimed at treating diabetic peripheral neuropathic pain (DPNP) at multiple medical meetings [1][5][6] Group 1: Clinical Data and Presentations - The clinical data will be discussed at three upcoming medical meetings: NeuroDiab in Bucharest, EASD in Vienna, and Arrowhead's Annual Pain Therapeutics Summit in San Diego [2][3][4] - A specific presentation titled "New Promise for Painful Diabetic Neuropathy" will take place on September 13, 2025, by Dr. Rodica Pop-Busui [7] - The Phase 2b study results will be presented on September 17, 2025, also by Dr. Rodica Pop-Busui, focusing on pilavapadin's efficacy in DPNP [7] Group 2: Product Information - Pilavapadin (LX9211) is a once-daily, orally delivered, selective small molecule inhibitor of AAK1, which targets neuropathic pain without affecting opiate pathways [5] - Preclinical studies indicate that pilavapadin penetrates the central nervous system and reduces pain behavior in neuropathic pain models [5] Group 3: Company Overview - Lexicon Pharmaceuticals is focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to identify therapeutic protein targets [6] - The company has a pipeline of drug candidates in various stages of discovery and development, addressing multiple indications including neuropathic pain and metabolic disorders [8]